OLDWICK, N.J., Oct. 29, 2019 /PRNewswire/ -- Provention Bio,
Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company
dedicated to intercepting and preventing immune-mediated disease,
today announced that it will report its third quarter 2019
financial results on Tuesday, November 5,
2019.
In connection with the earnings release, Provention's management
team will host a live conference call and webcast at 4:30 PM ET on
Tuesday, November 5, 2019, to discuss
the Company's financial results and provide a corporate update.
Conference Call Information
To access the call, please
dial 1-877-870-4263 (domestic) or 1-412-317-0790 (international)
five minutes prior to the start time and ask to be connected to the
"Provention Bio Call". An audio webcast will also be available in
the "Events and Webcasts" page in the Investors page of the
Company's website, www.proventionbio.com. An archived webcast
will be available on the Company's website approximately two hours
after the conference call and will be available for 30 days
following the call.
About Provention Bio, Inc.
Provention Bio, Inc.
(Nasdaq: PRVB) is a clinical-stage biopharmaceutical company
leveraging a transformational drug development strategy that is
focused on the prevention or interception of immune-mediated
disease. Provention's mission is to in-license, transform
and develop therapeutic candidates targeting the high morbidity,
mortality and escalating costs of autoimmune and inflammatory
diseases including: type 1 diabetes (T1D), Crohn's disease, celiac
disease, and lupus. Provention's diversified portfolio includes
advanced-stage product development candidates that have undergone
clinical testing by other companies.
Investors:
Sam Martin, Argot Partners
sam@argotpartners.com
212-600-1902
Media:
David Rosen, Argot Partners
david.rosen@argotpartners.com
212-600-1902
View original content to download
multimedia:http://www.prnewswire.com/news-releases/provention-bio-to-report-third-quarter-2019-financial-results-and-host-conference-call-on-tuesday-november-5-2019-300946841.html
SOURCE Provention Bio, Inc.